Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have a 85.71% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) overview
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing,and difficulty breathing. Treatment includes medications such as epinephrine, antihistamines, and corticosteroids.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
